SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 23, 2002
Keryx Biopharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
Delaware 000-30929 13-4087132
------------------------ ------------- ------------------
(State or other juris- (Commission (IRS Employer
diction of incorporation File Number) Identification No.)
101 Main Street, 17th Floor, Cambridge, MA 02142
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 494-5515
N/A
(Former name or former address, if changed since last report)
Item 5. Other Events.
On December 23, 2002, Keryx Biopharmaceuticals, Inc. announced the
appointment of Michael S. Weiss as its Chairman and Chief Executive Officer,
replacing Dr. Benjamin Corn, who resigned his position as President and Chief
Executive Officer effective on December 23, 2002. On December 23, 2002, Keryx
also announced that Dr. Morris Laster, its Executive Chairman, resigned his
position effective immediately.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
The exhibit filed as part of this Current Report on Form 8-K is listed on
the Exhibit Index immediately preceding such exhibit, which Exhibit Index is
incorporated herein by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: December 24, 2002 KERYX BIOPHARMACEUTICALS, INC.
By: /s/ Michael S. Weiss
------------------------
Michael S. Weiss
Chairman and Chief Executive
Officer
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press release dated December 23, 2002